RxDoctor Payments Data

George Small, MD

Neurology · Pittsburgh, PANPI 1821099011

Payments from drug & device makers

$269,348in general payments, 2019–2025

Across 200 payments — averaging $1346.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$120K
  • Amgen$68K
  • AstraZeneca$55K
  • UCB Biosciences Inc.$19K
  • Alnylam Pharmaceuticals Inc.$2K
  • AbbVie$1K
  • plus $2K from 10 others

What the payments were for

  • Consulting fees$7,36512%
  • Speaking & faculty fees$43,46571%
  • Travel & lodging$4,7708%
  • Food & beverage$5,3749%
  • Education$1420%
  • Gifts$2250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA19$120,166
Amgen(2 entities)5$68,419
AstraZeneca(2 entities)75$55,486
UCB Biosciences Inc.8$19,421
Alnylam Pharmaceuticals Inc.9$2,159
AbbVie(2 entities)57$1,289
Sanofi2$1,048
Argenx US, Inc.8$419
UCB, Inc.4$253
Saol Therapeutics Inc.3$225
Johnson & Johnson3$157
Biogen2$121
Genentech, Inc.2$100
Sanofi-aventis U.S. LLC1$35
Takeda Pharmaceuticals U.S.A., Inc.1$27
Eisai Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$269,348 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$113,559
Medicare patients
287
Services billed
5,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5035$333,377
Gamunex-CImmune Globul G/Gly/Iga Avg 4623$144,468
PanzygaImmun Glob G(Igg)-Ifas/Glycine13$118,338
Pyridostigmine Bromide302$23,906
Pyridostigmine Bromide ErPyridostigmine Bromide46$20,326
BotoxOnabotulinumtoxina11$13,517
Azathioprine54$3,509
Gabapentin148$3,127
Mycophenolate Mofetil27$2,641
Prednisone332$2,411
Pregabalin34$2,141
Memantine Hcl ErMemantine Hcl13$1,895
Glycopyrrolate53$1,893
Carbamazepine21$1,445
Duloxetine Hcl82$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$27$333,37735 claims
AbbVieBotox$1,289$13,51711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →